ライフサイエンスコーパス: tetanus toxoid

1 of interferon-gamma, after stimulation with tetanus toxoid.

2 kin-13 (0.52, 0.34-0.82, 0.0005) response to tetanus toxoid.

3 d invariably showed the greatest response to tetanus toxoid.

4 SCs to recall antigens, Candida albicans and Tetanus toxoid.

5 eration, but not of responses resulting from tetanus toxoid.

6 in the lymphocyte proliferative response to tetanus toxoid.

7 blocked Ag-specific T cell proliferation to tetanus toxoid.

8 oth at the time of primary immunization with tetanus toxoid.

9 o influence on the proliferative response to tetanus toxoid.

10 ith purified type VI and VIII CPS coupled to tetanus toxoid.

11 ay MLR, and a response to soluble recall Ag, tetanus toxoid.

12 avidly to protein A and weakly to ssDNA and tetanus toxoid.

13 inhibit the primary immunization of mice to tetanus toxoid.

14 4+ cell lines propagated by stimulation with tetanus toxoid.

15 immunisation coverage of pregnant women with tetanus toxoid.

16 red with other HIV antigens (such as p24) or tetanus toxoid.

17 ence in the increases in antibody binding to tetanus toxoid.

18 en because MSCs did not affect challenges to tetanus toxoid.

19 At 12 wk, tetanus toxoid (0.5 mL intramuscular) and Pneumovax II v

20 (PRP) after 1, 2, or 3 doses of a diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccine combi

21 polysaccharide (MCC) and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenz

22 ks) infants to receive 3 doses of diphtheria-tetanus toxoids-acellular pertussis-hepatitis B virus-in

23 Three primary doses of the diphtheria-tetanus toxoids-acellular pertussis-inactivated poliomye

24 has been included in the combined diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovir

25 ontrol mice at the time of immunization with tetanus toxoid adsorbed to aluminum hydroxide (TT/Alum).

26 LR using naive CD4(+) T cells, and inhibited tetanus toxoid Ag presentation by DCs.

27 into the ON/E but not the OB, whereas (125)I-tetanus toxoid alone did not penetrate into the CNS.

28 ast Sweden cohort, were stimulated with Ags (tetanus toxoid and beta-lactoglobulin) and diabetes-rela

29 on index [SI]) as well as to present soluble tetanus toxoid and candida albicans (10- to 100-fold inc

30 al proteins NS3 and NS5, and recall antigens tetanus toxoid and Candida.

31 ltures and then compared with controls using tetanus toxoid and frozen/thawed third-party cells with

32 ch mAb, MLN-7 (gamma1, kappa), was raised to tetanus toxoid and had no identified cross-reactivity.

33 caques that were immunized sequentially with tetanus toxoid and hepatitis A virus failed to develop a

34 donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N

35 e significant effect on antibody production, tetanus toxoid and measles IgG levels remained unchanged

36 Hapten 1 was conjugated to tetanus toxoid and mixed with liposomes containing monop

37 phocyte reaction, and normal Ab titers after tetanus toxoid and pneumovax immunization.

38 We studied the memory cells specific for tetanus toxoid and purified protein derivative in 18 hea

39 e capsule, coupled by reductive amination to tetanus toxoid and purified recombinant GBM porin (rPorB

40 XmAb5871 suppressed humoral immunity against tetanus toxoid and reduced serum IgM, IgG, and IgE level

41 investigated in in vitro cocultures by using tetanus toxoid and Salmonella species as antigen models.

42 is profile also improved immune responses to tetanus toxoid and subunit influenza vaccine but not, a

43 n demonstrated to maternal immunization with tetanus toxoid and to congenital infections such as rube

44 duration at 24 h and individual responses to tetanus toxoid and Trichophyton mentagrophytes were sign

45 t of a nationally distributed diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine w

46 safety study of a combination diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP),

47 cts received a single dose of diphtheria and tetanus toxoids and acellular pertussis vaccine 10 years

48 estational age and receipt of diphtheria and tetanus toxoids and acellular pertussis vaccine.

49 jugate, human papillomavirus, diphtheria and tetanus toxoids and acellular pertussis, and tetanus and

50 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, meningococcal c

51 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, pneumococcal co

52 %) had received >/=3 doses of diphtheria and tetanus toxoids and aP vaccine at the time of their firs

53 completion, which included 4 diphtheria and tetanus toxoids and pertussis, 3 poliovirus, and 1 measl

54 es-mumps-rubella; poliovirus; diphtheria and tetanus toxoids and pertussis; Haemophilus influenzae ty

55 a and a decreased response to diphtheria and tetanus toxoids and to meningococcal, salmonella, and Ha

56 The administration of the diphtheria and tetanus toxoids and whole-cell pertussis (DTP) vaccine a

57 s against these antigens, a control antigen (tetanus toxoid), and phytohemaglutinin were determined i

58 eonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine has been

59 Currently inactivated influenza, tetanus toxoid, and acellular pertussis vaccines are rec

60 DNA), anti-extractable nuclear antigen, anti-tetanus toxoid, and antibodies to pneumococcal capsular

61 xoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant,

62 Proliferative responses to PHA, anti-CD3, tetanus toxoid, and dengue Ags were decreased significan

63 y or intranasally with GAS CHO conjugated to tetanus toxoid, and mortality and oral colonization were

64 irus type 1 (HIV-1) envelope (Env) peptides, tetanus toxoid, and phytohemagglutinin was measured in p

65 e prepared by coupling S. suis type 2 CPS to tetanus toxoid, and the immunological features of the po

66 Undervaccination for the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine.

67 oped hybrid TT-OVA-PeptiCRAd containing both tetanus toxoid- and tumor-specific peptides.

68 We also determined levels of anti-tetanus toxoid (anti-TT) as a non-oral antigen control.

69 In normal rhesus monkeys immunized with tetanus toxoid, anti-CD20 treatment and resulting deplet

70 ith tetanus fragment C and CT developed anti-tetanus toxoid antibodies and were protected against sys

71 Anti-tetanus toxoid antibody IgG geometric mean concentration

72 Both groups had significant increases in tetanus toxoid antibody levels after vaccination but wit

73 e hypersensitivity, CD4 and CD8 counts, anti-tetanus toxoid antibody levels, erythrocyte complement r

74 affect preexisting antipneumococcal or anti-tetanus toxoid antibody levels.

75 i-PRP (from 5.25 to 2.68 microg/mL) and anti-tetanus toxoid antibody responses (from 0.13 to 0.09 Eq/

76 that CD34(+)/CD86(+) cells can also present tetanus toxoid antigen to memory CD4(+) T cells.

77 rved after the fifth injection of diphtheria-tetanus toxoids-aP (DTaP) vaccine.

78 characterization of memory B cells by using tetanus toxoid as a model antigen.

79 reduced T cell proliferation in response to tetanus toxoid as a recall Ag.

80 the skin, using diphtheria toxoid (DTx) and tetanus toxoid as model antigens.

81 n of the group A polysaccharide and used its tetanus toxoid as the carrier protein to produce the now

82 ningococcal conjugate vaccine that used SIIL tetanus toxoid as the carrier protein.

83 nses to the T cell-dependent protein antigen tetanus toxoid as well as DTH responses were preserved i

84 < 0.01) but an increased immune response to tetanus toxoid, beta-lactoglobulin, and the autoantigens

85 ntrol antigens (glutathionine-S-transferase, tetanus toxoid, Candida albicans, mumps, bovine serum al

86 ation with irradiated anti-RNP (but not anti-tetanus toxoid) CD4(+) cells induced remission of anti-R

87 , B cells and moDCs were pulsed with IgE-NIP-tetanus toxoid complexes and cocultured with autologous

88 ctionally active IgG in response to a dV CPS-tetanus toxoid conjugate (dV-TT), and 98% of neonatal mi

89 A GBS type III capsular polysaccharide (CPS)-tetanus toxoid conjugate (III-TT) vaccine was evaluated

90 his study, Neisseria meningitidis group C PS-tetanus toxoid conjugate (MCPS-TT) vaccine was used to e

91 oci (XenoMouse mice) vaccinated with a PPS-3-tetanus toxoid conjugate and their molecular genetic str

92 e protein A) or a capsular 6B polysaccharide-tetanus toxoid conjugate induced mucosal and systemic an

93 s incorporated into the original beta-mannan tetanus toxoid conjugate providing a tricomponent conjug

94 cine against Candida albicans, a beta-mannan tetanus toxoid conjugate showed poor immunogenicity in m

95 and capsular group C Neisseria meningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administ

96 A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) wa

97 ly from those obtained with the type III CPS-tetanus toxoid conjugate vaccine and the unconjugated tw

98 V is a single-dose typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine for persons >/=6 months

99 y determined the effectiveness of a fentanyl-tetanus toxoid conjugate vaccine to alter fentanyl self-

100 wledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established hu

101 sera from women receiving a GBS type III PS-tetanus toxoid conjugate vaccine, and sera from nonimmun

102 ia meningitidis group A (NmA) polysaccharide-tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), d

103 antibody (MAb) prepared against a N-Pr MBPS-tetanus toxoid conjugate vaccine.

104 A monovalent MenA polysaccharide-tetanus toxoid conjugate was therefore developed.

105 of 4 vaccines: Vi-polysaccharide (Vi-PS), Vi-tetanus-toxoid conjugate vaccine (Vi-TT), live oral Ty21

106 jugated to the carrier proteins CRM(197) and tetanus toxoid did not engage TLR2 on HEK or dendritic c

107 individuals with the common recall antigen, tetanus toxoid, disrupts this steady state, resulting in

108 Mice were injected subcutaneously with dLOS-tetanus toxoid (dLOS-TT), dLOS-high-molecular-weight pro

109 intramuscular injections of dLOS-conjugated tetanus toxoid, dLOS-conjugated high-molecular-weight pr

110 C-PS, a TI Ag, or a conjugate of MenC-PS and tetanus toxoid elicited an augmented PS-specific IgG res

111 nistration of QS-21 with the vaccine protein tetanus toxoid elicited strong serum IgM and IgG Ab resp

112 e other hybrid when used in conjunction with tetanus toxoid for intranasal immunization of BALB/c mic

113 T cell lines specific for B. burgdorferi and tetanus toxoid from subjects with chronic B. burgdorferi

114 pathogen group B streptococci conjugated to tetanus toxoid (GBSIII-TT) as our model vaccine.

115 r polysaccharide vaccine glucuronoxylomannan-tetanus toxoid (GXM-TT) have been shown to be biological

116 Pre-existing immunity to tetanus toxoid had no effect on the induction of AH1-spe

117 re smaller, proliferated well in response to tetanus toxoid, had longer telomeres, and expressed gene

118 e larger, proliferated poorly in response to tetanus toxoid, had shorter telomeres, and expressed gen

119 tussis vaccines combined with diphtheria and tetanus toxoids have proven to be well tolerated, immuno

120 t the preclinical development of recombinant tetanus toxoid heavy chain fragment (rTTHC) linked to FP

121 fection or immunizations to influenza virus, tetanus toxoid, hepatitis B Ag, and human papillomavirus

122 made with the HMW polysaccharide coupled to tetanus toxoid (HMW-TT) conferred better protection agai

123 zation of healthy adults with GBS type Ia PS-tetanus toxoid (Ia-TT) or Ib-TT glycoconjugate vaccines

124 iencies and stunting, but many had titers of tetanus toxoid IgG antibodies below the protective conce

125 and M (IgM)], hepatitis A virus, rotavirus, tetanus toxoid (IgG), and a panel of recombinant malaria

126 Measles and tetanus toxoid IgGs were measured quantitatively by usin

127 Adsorption of GBS type III CPS-tetanus toxoid (III-TT) conjugate vaccine to alum did no

128 Streptococcus (GBS) type III polysaccharide-tetanus toxoid (III-TT) conjugate.

129 Measles and tetanus toxoid immunisation were not affected.

130 ells, peripheral plasmablasts isolated after tetanus toxoid immunization and memory B cells isolated

131 ent conjugate of (poly)glycerolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides pr

132 galovirus, varicella-zoster virus (VZV), and tetanus toxoid in normal controls, long-term nonprogress

133 s of AMA and responses to a control antigen, tetanus toxoid, in supernatants.

134 -2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HI

135 etyl PSA Ags were prepared and conjugated to tetanus toxoid, including completely de-N-acetylated PSA

136 from complete ISCOMs (i.e., with an antigen (tetanus toxoid) incorporated) can be modeled as a polydi

137 Tetanus toxoid-induced human PBMC IL-5 and IL-13 secreti

138 ion of monocyte-derived dendritic cells, and tetanus toxoid-induced PBMC proliferation were assessed

139 Surprisingly, in the ISCOMs, the tetanus toxoid is located just below the membrane inside

140 Escherichia coli K92 capsular polysaccharide-tetanus toxoid (K92-TT) conjugate vaccine are here evalu

141 Stimulation with tetanus toxoid led to an increased proportion of CD45RA+

142 ia meningitidis group C (MCPS) conjugated to tetanus toxoid (MCPS-TT) and the same response in BALB/c

143 onjugated to proteins, e.g., MCPS coupled to tetanus toxoid (MCPS-TT), elicits a thymus-dependent (TD

144 tomegalovirus-pp65 (immunodominant protein), tetanus toxoid, measles, mumps, and rubella.

145 The rAls3p-N vaccine, but neither tetanus toxoid nor a related Als protein (Als5p), improv

146 Serum levels of RF, but not those of anti-tetanus toxoid or anti-pneumococcal polysaccharide antib

147 jugated to proteins, e.g., MCPS coupled with tetanus toxoid or the diphtheria toxin derivative CRM197

148 to recall Ags (purified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite

149 were intranasally immunized with ovalbumin, tetanus toxoid, or influenza virus either alone or toget

150 etic of GXM, P13, to either BSA, P13-BSA, or tetanus toxoid, P13-tetanus toxoid, was examined in BALB

151 systemic reactions observed with diphtheria-tetanus toxoids-pertussis vaccine but has not eliminated

152 dies when immunized orally with a vaccine of tetanus toxoid plus cholera toxin as adjuvant.

153 One-year-old mice given nasal tetanus toxoid plus the chimeric toxin as adjuvant were

154 l polysaccharide of serotype 1 conjugated to tetanus toxoid (Pnc1-TT) as a model vaccine.

155 Tetanus toxoid, pneumococcal polysaccharide, and KLH vac

156 y less than that in animals immunized with a tetanus toxoid-polysaccharide conjugate.

157 ce with a conjugate of PPS of serotype 3 and tetanus toxoid (PPS3-TT) and determined the antibody res

158 ific for epitopes of HCMV phosphoprotein-65, tetanus toxoid precursor, EBV nuclear Ag 2, or HIV gag p

159 toxin C fragment (TTCF), a component of the tetanus toxoid present in the diphtheria, tetanus and pe

160 confirm the constructive function of AEP in tetanus toxoid processing, but they are discordant with

161 coccal capsular polysaccharide conjugated to tetanus toxoid produce Abs that can be either protective

162 acetyl-XGKGKGKGCONH2 (where X represents the tetanus toxoid promiscuous T cell epitope (TT) sequence

163 iour and unlike the previously characterised tetanus toxoid protein (slightly extended and hydrodynam

164 th a then-new meningococcal A polysaccharide-tetanus toxoid protein conjugate vaccine (PsA-TT, or Men

165 d testing of the newly WHO-prequalified ViPS-tetanus toxoid protein conjugate vaccine, providing effi

166 Conjugation with tetanus toxoid protein however greatly increased the mol

167 indicated that HTL recall responses to whole tetanus toxoid protein were reduced in chronically infec

168 articular, MUC1 glycopeptide conjugates with Tetanus toxoid proved to be efficient vaccines inducing

169 erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of ane

170 is (DTaP) combined with Hib-PS conjugated to tetanus toxoid (PRP-T) and hepatitis B (HB) (DTaP-PRP-T-

171 PUB1 conjugated to tetanus toxoid (PUB1-TT) induced a type 8 PS-specific an

172 Tetanus toxoid reactive clones and a purified protein de

173 s generated from controls and in none of the tetanus toxoid-reactive T cell lines generated from eith

174 luster complex, keyhole limpit hemocyanin or tetanus toxoid-reactive Th cells promoted generation of

175 endation that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular

176 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

177 fant contact, receive a single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

178 In response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular

179 Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular

180 ia Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular

181 les for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced a

182 d to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine).

183 Tetanus toxoid resulted in even greater production.

184 Using tetanus toxoid specific and HLA-DR-restricted T lymphocy

185 Testing the distribution of tetanus toxoid-specific (TT(+)) mBCs revealed their pres

186 in MLA derivatives enhance the production of tetanus toxoid-specific antibodies in mice.

187 frag) induced significantly higher levels of tetanus toxoid-specific antibody than BRD509(pKK/C frag)

188 study the phenotype and frequency of D- and tetanus toxoid-specific B cells by culturing B cells in

189 Importantly, tetanus toxoid-specific IFN-gamma production by PBMC fro

190 The concentrations of tetanus toxoid-specific IgG also increased comparably an

191 Consistently, the avidity of tetanus toxoid-specific serum antibodies was substantial

192 RD509(pKK/ppagC/C frag)] mounted the highest tetanus toxoid-specific serum antibody response.

193 ve generated myelin basic protein (MBP)- and tetanus toxoid-specific T cell clones from CD45RA+/RO- a

194 Blockade of CD28 failed to inhibit tetanus toxoid-specific T cell proliferation in both the

195 s associated with significant improvement of tetanus-toxoid-specific T-cell response.

196 ociated with increased IL-2 expression after tetanus toxoid stimulation.

197 ll responses against autoantigen or repeated tetanus toxoid stimulations require both Kv1.3 and KCa3.

198 on of antibodies to a neutral antigen, i.e., tetanus toxoid, the consumption of IgG EndoCab antibody

199 OCs also present soluble protein tetanus toxoid to activate autologous CD4+ T cells.

200 e (IIIPS) or with IIIPS covalently linked to tetanus toxoid to assess specificity, sensitivity, and p

201 ls with CpG ODN also enabled presentation of tetanus toxoid to CD8(+) T cells, resulting in CD8(+) T

202 by reductive amination at multiple sites to tetanus toxoid to create a polysaccharide-protein conjug

203 retained the ability to process and present tetanus toxoid to T cells, which indicates that response

204 been eliminated to provide immunisation with tetanus toxoid to women of childbearing age.

205 Intranasal vaccination with (125)I-tetanus toxoid together with unlabeled CT as adjuvant re

206 Specific antibodies binding to tetanus toxoid (total IgG) and pneumococcal capsular pol

207 universal helper T lymphocyte (HTL) epitope tetanus toxoid (TT) 830-843.

208 igens, we compared the antibody responses to tetanus toxoid (TT) after tetanus vaccination in 193 sub

209 ally or orally to mice orally immunized with tetanus toxoid (TT) and CT to determine whether this cyt

210 ll as the proliferation of HLA-DR-restricted tetanus toxoid (TT) and influenza hemagglutinin-specific

211 ix-week-old C57BL/6 mice were immunized with tetanus toxoid (TT) and treated with RA and/or PIC at pr

212 neumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of

213 eningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a carrier protein (PsA-TT).

214 gG and B-cell receptor repertoires following tetanus toxoid (TT) booster vaccination.

215 Finally, the recall response to tetanus toxoid (TT) by PBMC from individuals vaccinated

216 BALB/c mice were nasally immunized with tetanus toxoid (TT) combined with CT, and the responses

217 mmunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants

218 type II or III capsular polysaccharide (CPS)-tetanus toxoid (TT) conjugate vaccines combined in a sin

219 However, tolerant mice immunized with tetanus toxoid (TT) developed high anti-TT antibody, dem

220 volvulus infection on the immune response to tetanus toxoid (TT) following tetanus vaccination was st

221 lines were generated to either MBP, PLP, or tetanus toxoid (TT) from 34 relapsing-remitting MS patie

222 cholera toxin (CT) on the immune response to tetanus toxoid (TT) given by intranasal or oral routes.

223 We assessed the impact of PsA-TT on tetanus toxoid (TT) immunity by quantifying age- and sex

224 sed as mucosal immunogen and as adjuvant for tetanus toxoid (TT) in mice.

225 nt influenza seasonal subunit vaccine and to tetanus toxoid (TT) in mouse.

226 train 26397 was detoxified and conjugated to tetanus toxoid (TT) or a cross-reactive mutant (CRM) of

227 P13 was conjugated to tetanus toxoid (TT) or diphtheria toxoid (DT) and admini

228 s antigen-presenting cells for either intact tetanus toxoid (TT) or for a TT peptide.

229 The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (H

230 gens, hPBMC were cultured in the presence of tetanus toxoid (TT) or phytohemagglutinin (PHA) and eith

231 was isolated, detoxified, and conjugated to tetanus toxoid (TT) or the cross-reactive mutant (CRM) o

232 ells and present an exogenous DR1-restricted tetanus toxoid (TT) peptide, indicating that the transdu

233 (+) T cells that proliferated in response to tetanus toxoid (TT) presented by autologous CD B cells.

234 coccal capsular polysaccharide conjugated to tetanus toxoid (TT) produce Abs that, based on the epito

235 oconjugate made by conjugating this with the tetanus toxoid (TT) protein have been characterized and

236 polysaccharides, and very different from the tetanus toxoid (TT) protein used for the conjugation.

237 rhoptry-associated protein-1 [RAP-1]) and to tetanus toxoid (TT) tested using enzyme-linked immunosor

238 osaccharide units (9Glc-NH(2)) conjugated to tetanus toxoid (TT) to induce antibodies in rabbits.

239 ns, individual GBS CPSs have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced im

240 ion, individual GBS CPS have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced im

241 In clinical trials, maternal tetanus toxoid (TT) vaccination is effective in protecti

242 eive an intramuscular dose of GBS type V CPS-tetanus toxoid (TT) vaccine (n=15), GBS type V CPS-cross

243 present study, we hypothesized that the anti-tetanus toxoid (TT) vaccine response of neonatal mice co

244 Tetanus toxoid (TT) was encapsulated in microparticles p

245 dLOS-OMP and OS-OMP conjugates, while a dLOS-tetanus toxoid (TT) was synthesized for comparison.

246 MV infection or were recently immunized with tetanus toxoid (TT) were included as controls.

247 dinium tetrafluoroborate (CDAP) and bound to tetanus toxoid (TT) with adipic acid dihydrazide as a li

248 IgA1 antibodies against a systemic antigen, tetanus toxoid (TT), and a mucosal antigen, Helicobacter

249 CFSE-labeled PBMCs were stimulated with CMV, tetanus toxoid (TT), and C albicans antigens and subsequ

250 entous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were mea

251 ve SLE patients immunized with pneumococcal, tetanus toxoid (TT), and Haemophilus influenzae type B (

252 hoproliferative responses to HIV-1 antigens, tetanus toxoid (TT), and mitogens were measured and corr

253 hly purified ganglioside G(D1a), pulsed with tetanus toxoid (TT), and washed, the expected Ag-induced

254 red in the presence of either recall antigen tetanus toxoid (TT), anti-CD3 (OKT3) monoclonal antibody

255 roteins, keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), as well as an HLA A2.1-restricted i

256 Conjugate vaccines were created by coupling tetanus toxoid (TT), gp120, and/or env2-3 with group B s

257 y normal human mononuclear cells, induced by tetanus toxoid (TT), human thyroglobulin (TG), Escherich

258 encapsulation of two antigens, ovalbumin and tetanus toxoid (TT), in PLGA microspheres was adjusted b

259 D4(+) T cells via a carrier protein, such as tetanus toxoid (TT), resulting in the induction of PS-sp

260 ponded to vaccination with GXM conjugated to tetanus toxoid (TT), the relative magnitude of the antib

261 C meningococcal polysaccharides, as well as tetanus toxoid (TT), was used to investigate the BCR rep

262 ry to activate myelin basic protein (MBP) or tetanus toxoid (TT)-reactive CD4 T cells were compared b

263 Tetanus toxoid (TT)-specific antibody avidity was increa

264 gand (rCD40L)-activated non-T cells, whereas tetanus toxoid (TT)-specific clones exhibited only helpe

265 olysaccharide (GBSIII) to ovalbumin (OVA) or tetanus toxoid (TT).

266 t B. anthracis protective antigen (rPA), and tetanus toxoid (TT).

267 subjects following a booster injection with tetanus toxoid (TT).

268 toxins were coadministered with radiolabeled tetanus toxoid (TT).

269 heir nasal delivery with the protein vaccine tetanus toxoid (TT).

270 estricted influenza matrix peptide (MP), and tetanus toxoid (TT).

271 HIV-1 envelope glycoprotein (CN54gp140) and tetanus toxoid (TT).

272 and lack of lymphoproliferative response to tetanus toxoid (TT; 73%) after immunization and impaired

273 d spontaneously respond to a recall antigen (tetanus toxoid [TT] vaccine) or respond to a recall anti

274 unogenicity of combining 2 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) with diphtheria-TT-a

275 Immunization of mice with tetanus toxoid-type III polysaccharide conjugate did not

276 g cells we measure in mice immunized against Tetanus Toxoid under largely varying conditions (antigen

277 ived from cucumber mosaic virus containing a tetanus toxoid universal T-cell epitope (CuMVTT).

278 rozoite surface protein (MSP-1(19)) fused to tetanus toxoid universal T-cell epitopes P30 and P2.

279 of type V GBS capsular polysaccharide (CPS)-tetanus toxoid (V-TT) conjugate vaccine (CV) were assess

280 who received their first dose of PRP-T after tetanus toxoid vaccination, disease was unlikely from 1

281 Responses to tetanus toxoid vaccine (>or=4-fold rise) were similar in

282 received GBS type Ia capsular polysaccharide-tetanus toxoid vaccine (Ia CPS-TT), Ib CPS-TT, or III CP

283 aluminum phosphate, a commercially available tetanus toxoid vaccine adjuvanted with potassium alum, a

284 Moreover, topical delivery of tetanus toxoid vaccine to mice using STAR particles gene

285 erated after immunizations with conventional tetanus toxoid vaccine, and (2) preventing pathological

286 sily prevented by maternal immunisation with tetanus toxoid vaccine, and aseptic obstetric and postna

287 ricomponent vaccine, but not the beta-mannan tetanus toxoid vaccine, showed activation of BMDCs.

288 ur cells in culture, while MUC1 glycopeptide-Tetanus toxoid vaccines elicited antibodies in mice whic

289 mended to replace the booster diphtheria and tetanus toxoid vaccines in adolescents.

290 When used as an adjuvant for tetanus toxoid vaccines, certain MLA derivatives enhance

291 es may be alternatives to GBS polysaccharide-tetanus toxoid vaccines, eliciting additional antibodies

292 th 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines.

293 Antibody immunity to tetanus toxoid was assessed as a control.

294 by the investigational conjugate vaccine GXM-tetanus toxoid was examined.

295 The change in response to tetanus toxoid was significantly different from that of

296 f alpha4beta7 on T cells specific for KLH or tetanus toxoid was studied.

297 either BSA, P13-BSA, or tetanus toxoid, P13-tetanus toxoid, was examined in BALB/c and CBA/n mice th

298 plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups.

299 omain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined.

300 Pf merozoite surface protein-1 (MSP-1), and tetanus toxoid were measured by indirect enzyme-linked i